Abstract
Today, it is of great importance to timely inform health care professionals and patients about the risks associated with the use of medicinal products (MP) in order to minimize the development of undesirable effects of pharmacotherapy. The easiest way to convey this information to the end-user is to make changes in the general characteristics of a medicinal preparation (SmPC) and the instruction for medical use (IFU)/package leaflet (PL). To maintain up-to-date information in the SmPC and IFU/PL, it is necessary to constantly monitor new information on the efficacy and safety of medicinal products. The article presents data on the implementation of routine risk minimization measures associated with the discovery of new and relevant information on safety in relation to MP produced by RUE «Belmedpreparaty» in 2018-2020. At the moment, the company produces a wide range of medicines, therefore, the implementation of constant monitoring of such information for further updating of information about the drug is an important link in the work of the pharmacovigilance department.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have